{
    "data": [
        {
            "id": "4033309",
            "type": "article",
            "attributes": {
                "publishOn": "2016-12-29T15:00:46-05:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Chemours Debt, Legal Overhang Should Price It Closer To $14",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "70965",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "233550",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "522735",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4033309-chemours-debt-legal-overhang-should-price-closer-to-14"
            }
        },
        {
            "id": "4028194",
            "type": "article",
            "attributes": {
                "publishOn": "2016-12-06T06:00:00-05:00",
                "isLockedPro": false,
                "commentCount": 78,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Chemours: Lessons Learned From An Over 300 Percent Gain (Our 2016 Pick Of The Year)",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "67985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "522735",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4028194-chemours-lessons-learned-from-over-300-percent-gain-2016-pick-of-year"
            }
        },
        {
            "id": "4026317",
            "type": "article",
            "attributes": {
                "publishOn": "2016-11-25T11:22:46-05:00",
                "isLockedPro": false,
                "commentCount": 29,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Chemours: Risks Reduced, Moving To The Sidelines",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "54092",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "522735",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4026317-chemours-risks-reduced-moving-to-sidelines"
            }
        },
        {
            "id": "4014208",
            "type": "article",
            "attributes": {
                "publishOn": "2016-10-24T10:04:19-04:00",
                "isLockedPro": false,
                "commentCount": 30,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Honeywell And Chemours Seize Climate Change Deal Opportunity",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71185",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "179747",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "522735",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4014208-honeywell-and-chemours-seize-climate-change-deal-opportunity"
            }
        },
        {
            "id": "4010975",
            "type": "article",
            "attributes": {
                "publishOn": "2016-10-08T19:32:28-04:00",
                "isLockedPro": false,
                "commentCount": 58,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Chemours: Strong Sell Given Absurd Risk Profile",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "54092",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "233018",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "522735",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4010975-chemours-strong-sell-given-absurd-risk-profile"
            }
        },
        {
            "id": "4008732",
            "type": "article",
            "attributes": {
                "publishOn": "2016-09-28T05:00:00-04:00",
                "isLockedPro": false,
                "commentCount": 34,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Chemours Vs. Olin Corporation: And The Winner Is?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "67985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "522735",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4008732-chemours-vs-olin-corporation-and-winner-is"
            }
        },
        {
            "id": "4007668",
            "type": "article",
            "attributes": {
                "publishOn": "2016-09-21T16:47:49-04:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Chemours Company: Five Reasons To Go Short At These Levels",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102253",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "232927",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "522735",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4007668-chemours-company-five-reasons-to-go-short-levels"
            }
        },
        {
            "id": "3999762",
            "type": "article",
            "attributes": {
                "publishOn": "2016-08-15T22:41:56-04:00",
                "isLockedPro": false,
                "commentCount": 43,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Chemours: The Dangers Of Following An Unbalanced Short Thesis",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "67985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "177190",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "522735",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3999762-chemours-dangers-of-following-unbalanced-short-thesis"
            }
        },
        {
            "id": "3987528",
            "type": "article",
            "attributes": {
                "publishOn": "2016-07-11T09:43:22-04:00",
                "isLockedPro": false,
                "commentCount": 65,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Chemours: Heading To $0? Not Likely As Outsized Gains Are More Probable",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "67985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "175736",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "522735",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3987528-chemours-heading-to-0-not-likely-outsized-gains-are-probable"
            }
        },
        {
            "id": "3980406",
            "type": "article",
            "attributes": {
                "publishOn": "2016-06-07T10:05:57-04:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Andrew Left: Right Again?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23998",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "522735",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3980406-andrew-left-right-again"
            }
        },
        {
            "id": "3980056",
            "type": "article",
            "attributes": {
                "publishOn": "2016-06-06T07:25:39-04:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Chemours Is A Bankruptcy Waiting To Happen! Chemours Was Purposely Designed For Bankruptcy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20335",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "232210",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "522735",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3980056-chemours-is-bankruptcy-waiting-to-happen-chemours-was-purposely-designed-for-bankruptcy"
            }
        },
        {
            "id": "3972380",
            "type": "article",
            "attributes": {
                "publishOn": "2016-05-06T13:08:24-04:00",
                "isLockedPro": false,
                "commentCount": 68,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Spin-Off In The Spotlight: The Chemours Company",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "85646",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "522735",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3972380-spin-off-in-spotlight-chemours-company"
            }
        },
        {
            "id": "3826906",
            "type": "article",
            "attributes": {
                "publishOn": "2016-01-22T07:04:10-05:00",
                "isLockedPro": false,
                "commentCount": 36,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Chemours Company: Toxic Stock Proved To Be A Gem",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "99436",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "168561",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "522735",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/3826906-chemours-company-toxic-stock-proved-to-be-gem"
            }
        }
    ]
}